NTSR1 as a Radioligand Therapy Target

NTSR1, neurotensin receptor 1, is a cell-surface protein (GPCR). No tumor protein staining is recorded for it in Human Protein Atlas immunohistochemistry. Published literature reports that NTSR1 internalizes after ligand binding, which helps retain a radionuclide inside tumor cells. Clinical status: Discovery-stage (no clinical drug program).

Is NTSR1 a good radioligand therapy target?

Scored against the six criteria that decide whether a protein can become a radioligand therapy:

• ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
• ❌ Tumor expression: No tumor staining in HPA immunohistochemistry.
• ✅ Internalization: Reported to internalize, which favors radionuclide retention.
• ⚠️ Clinical precedent: Discovery-stage (no clinical drug program)
• ❔ Shedding: Not yet assessed.
• ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.

NTSR1 expression in cancer

No Human Protein Atlas tumor immunohistochemistry data is available for NTSR1.

Is NTSR1 internalized?

Yes. [68Ga]-Ga-SK01014 demonstrated significantly higher internalization and reduced efflux compared to [68Ga]-Ga-NT-20.3.

Sources: PMID 42206223 · PMID 42039273 · PMID 41877179 · PMID 40549484 · PMID 40101018. AI-extracted from abstracts, so verify before citing.

NTSR1 clinical trials

Discovery-stage (no clinical drug program). Nuclens hasn't indexed trials for NTSR1 yet. Search ClinicalTrials.gov for NTSR1 trials.

NTSR1 normal tissue expression

Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See NTSR1 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.

NTSR1 gene essentiality (DepMap)

CRISPR knockout effect across 1253 cancer cell lines: 0.11 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.